About Us > Management Team
Chairman of the Management Board
Tim Edwards is Chairman of the Management Board of ProtAffin for a fixed period until the Summer 2013, having stepped off the Supervisory Board to take on this assignment. He is an entrepreneur working in the biotechnology and charitable sectors. He is Chairman of Oxagen Limited, based in Oxford; Chairman of the UK BioIndustry Association, London; a member of UK Dept. of Health ‘Ministerial Industry Strategy Group’ and a member of the UK Dept for Business Innovation & Skills ‘Senior Industry Group’[Life Sciences]. Tim is also Chairman of The Mulberry Bush School for children aged 5-12 with severe emotional and behavioural difficulties; Chairman of Governors of Magdalen College School, Oxford a day school for pupils aged 7-18 with a co-educational sixth form; and a Fellow of the RSA, a charity founded in 1754 which drives ideas, innovation and social change. Until recently, upon its cash sale to GSK, Tim was President and Chief Executive Officer of Cellzome Inc, a privately-owned drug discovery company with a world-leading chemoproteomics technology platform.
Prof. Andreas Kungl
Chief Scientific Officer
Andreas is co-founder and CSO of ProtAffin. He is Professor at the University of Graz and, before joining ProtAffin, he worked at the Max Planck Biochemistry Institute in Martinsried, Germany, and at the Novartis Research Institute in Vienna for five years. Andreas has coordinated a number of national and European projects in the field of chemokine therapeutic strategies, protein-glycan interactions and glycomics. Andreas is a recognised authority in the basis of protein-glycan interactions.
Dr Mike Bartley
Chief Development Officer
Mike is Chief Development Officer of ProtAffin AG since 2011. He has worked for the last 10 years for Pfizer Inc, most recently leading early clinical- stage projects in respiratory diseases, taking several anti-inflammatory candidates from novel mechanistic classes into the clinic. Mike studied at Imperial College London and Queen Mary College London, before joining ICI (Zeneca, Syngenta) agrochemicals, where he led projects in many R&D areas, several to project launch. Mike has published a number of scientific papers and is inventor on a number of patents.